TR201101807T2 - Rosuvastatin kalsiyumun farmasotik bileşimleri - Google Patents

Rosuvastatin kalsiyumun farmasotik bileşimleri

Info

Publication number
TR201101807T2
TR201101807T2 TR2011/01807T TR201101807T TR201101807T2 TR 201101807 T2 TR201101807 T2 TR 201101807T2 TR 2011/01807 T TR2011/01807 T TR 2011/01807T TR 201101807 T TR201101807 T TR 201101807T TR 201101807 T2 TR201101807 T2 TR 201101807T2
Authority
TR
Turkey
Prior art keywords
pharmaceutical compositions
rosuvastatin calcium
rosuvastatin
sodium carbonate
anhydrous sodium
Prior art date
Application number
TR2011/01807T
Other languages
English (en)
Inventor
Far�� Ferhat
Apar� Serdar
Avci Recep
Original Assignee
Abd� �Brah�M �La� Sanay� Ve T�Caret Anon�M ��Rket�@
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abd� �Brah�M �La� Sanay� Ve T�Caret Anon�M ��Rket�@ filed Critical Abd� �Brah�M �La� Sanay� Ve T�Caret Anon�M ��Rket�@
Publication of TR201101807T2 publication Critical patent/TR201101807T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Buluş, rosuvastatinin veya farmasötik olarak kabul edilebilir tuzlarının; ağırlıkça %0.5 ile %2 oranında olması gereken susuz sodyum karbonat kullanımının sağlandığı, 0.1 N HCl ortamında dissolüsyon profilleri üzerine etkisi olan, özellikle rosuvastatinin kalsiyum tuzu ile susuz sodyum karbonat tuzunun farmasötik bileşimleri ile ilgilidir.
TR2011/01807T 2008-06-27 2008-06-27 Rosuvastatin kalsiyumun farmasotik bileşimleri TR201101807T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/052595 WO2009156796A1 (en) 2008-06-27 2008-06-27 Pharmaceutical compositions of rosuvastatin calcium

Publications (1)

Publication Number Publication Date
TR201101807T2 true TR201101807T2 (tr) 2012-02-21

Family

ID=40386506

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2011/01807T TR201101807T2 (tr) 2008-06-27 2008-06-27 Rosuvastatin kalsiyumun farmasotik bileşimleri

Country Status (19)

Country Link
US (1) US20110098315A1 (tr)
EP (1) EP2306982B1 (tr)
JP (1) JP2011525901A (tr)
KR (1) KR101283147B1 (tr)
AU (1) AU2008358622A1 (tr)
BR (1) BRPI0822782A2 (tr)
CA (1) CA2728539A1 (tr)
DK (1) DK2306982T3 (tr)
EA (1) EA201170101A1 (tr)
ES (1) ES2535106T3 (tr)
GE (1) GEP20135735B (tr)
IL (1) IL210102A0 (tr)
MA (1) MA32498B1 (tr)
MX (1) MX2010013834A (tr)
PT (1) PT2306982E (tr)
TN (1) TN2010000585A1 (tr)
TR (1) TR201101807T2 (tr)
WO (1) WO2009156796A1 (tr)
ZA (1) ZA201009057B (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2710540T5 (es) * 2010-06-30 2022-08-26 Mochida Pharm Co Ltd Preparación de compuesto de ácido graso omega-3
RO129060B1 (ro) * 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
KR102240429B1 (ko) * 2013-05-06 2021-04-15 한미약품 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
BR112017009521A2 (pt) 2014-11-11 2017-12-19 Shionogi & Co comprimido de múltiplas camadas que contém um fármaco instável à luz
JP6108635B2 (ja) * 2015-05-14 2017-04-05 ダイト株式会社 ロスバスタチン含有口腔内速崩壊錠
JP2022542004A (ja) 2019-07-31 2022-09-29 インタス ファーマシューティカルズ リミテッド ＨＭＧ－ＣｏＡレダクターゼ阻害剤及びフェノフィブラートを含む医薬組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2483099A1 (en) * 2002-05-03 2003-11-13 Hexal Ag Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ATE428411T1 (de) * 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
EP1905424A3 (en) * 2006-02-02 2008-04-30 Ranbaxy Laboratories Limited Process for the preparation of a pharmaceutical composition comprising stabilized statin particles
JP2009542693A (ja) * 2006-07-06 2009-12-03 テバ ファーマシューティカル インダストリーズ リミティド 薬物動態が制御された組成物
WO2008062476A2 (en) * 2006-10-31 2008-05-29 Glenmark Pharmaceutical Limited Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof

Also Published As

Publication number Publication date
CA2728539A1 (en) 2009-12-30
MA32498B1 (fr) 2011-07-03
MX2010013834A (es) 2011-02-21
US20110098315A1 (en) 2011-04-28
EP2306982B1 (en) 2015-01-07
EP2306982A1 (en) 2011-04-13
WO2009156796A1 (en) 2009-12-30
BRPI0822782A2 (pt) 2015-09-29
DK2306982T3 (en) 2015-04-20
ES2535106T3 (es) 2015-05-05
KR101283147B1 (ko) 2013-07-05
JP2011525901A (ja) 2011-09-29
KR20110027711A (ko) 2011-03-16
TN2010000585A1 (en) 2012-05-24
PT2306982E (pt) 2015-05-18
ZA201009057B (en) 2012-01-25
AU2008358622A1 (en) 2009-12-30
IL210102A0 (en) 2011-02-28
EA201170101A1 (ru) 2011-08-30
GEP20135735B (en) 2013-01-25

Similar Documents

Publication Publication Date Title
TR201101807T2 (tr) Rosuvastatin kalsiyumun farmasotik bileşimleri
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
EA201070786A1 (ru) Бензофуропиримидиноны
IN2012DN01233A (tr)
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
UA105229C2 (uk) Фармацевтичний склад
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
CL2012002716A1 (es) Uso de un compuesto inhibidores de dgat1 porque es útil en la prevención, demora del progreso o el tratamiento de una enfermedad o condición seleccionada a partir de quilomicronemia, síndrome de quilomicronemia familiar e hiperlipoproteinemia tipo v; un compuesto derivado de heteroarilo sustituido; composición farmacéutica.
DK2151241T3 (da) Stabilt fast præparat, omfattende 4,5-epoxymorphinanderivat
EA201101301A1 (ru) Натриевая соль 5-циклопропил-2-{[2-(2,6-дифторфенил)пиримидин-5-ил]амино}бензойной кислоты в качестве ингибиторов dhodh
MY165918A (en) Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
DOP2012000050A (es) Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina
CR20110209A (es) Composición farmacéutica sólida
SMT201400014B (it) Stabilita' di dissoluzione migliorata di compressedi carbonato di calcio
AR063027A1 (es) Derivados de sulfonamida
TR201001417A1 (tr) Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
UY32757A (es) Derivados de pirazoles, su preparacion y su aplicacion terapeutica
UA104420C2 (uk) Застосування похідних глутарової кислоти або їх фармацевтично прийнятних солей як протиаритмічних засобів
TW200833342A (en) 2-substituted pyrimidines I in therapy
ATE546448T1 (de) Urotensin-ii-rezeptorantagonisten
AR088398A1 (es) Preparacion de liberacion sostenida
PE20110564A1 (es) Composicion que tiene quitosano hidroxipropilo, amida y/o alquilo de acido dicarboxilico
TR201901012T4 (tr) Arteriosklerozun tedavisinde nor-safra asitlerinin kullanımı.
UA99199C2 (ru) Фармацевтические композиции розувастатина кальция